These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18264131)

  • 1. Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis.
    Kump E; Ji J; Wernli M; Häusermann P; Erb P
    Oncogene; 2008 Jun; 27(27):3856-64. PubMed ID: 18264131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis.
    Zhang D; Liu J; Wang Y; Chen J; Chen T
    J Cell Biochem; 2011 Nov; 112(11):3140-50. PubMed ID: 21695716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells.
    Jönsson G; Paulie S; Grandien A
    Anticancer Res; 2003; 23(2B):1213-8. PubMed ID: 12820373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
    Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
    Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
    Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
    Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gli2 expression and human bladder transitional carcinoma cell invasiveness.
    Mechlin CW; Tanner MJ; Chen M; Buttyan R; Levin RM; Mian BM
    J Urol; 2010 Jul; 184(1):344-51. PubMed ID: 20488474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
    Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
    Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
    Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.
    Kim Y; Yoon JW; Xiao X; Dean NM; Monia BP; Marcusson EG
    Cancer Res; 2007 Apr; 67(8):3583-93. PubMed ID: 17440069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.